Clinical Trials

Find a Trial

Trial Summary

Protocol No.S1500
StatusOPEN TO ACCRUAL
Principal InvestigatorLogan, Theodore
ScopeNational
PhasePhase II
Age GroupAdult
TitleA Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
DescriptionThis randomized phase II trial studies how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Males and Females of all ages
  • Diagnosis of renal cell carcinoma which is metastatic or locally advanced disease
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesKidney (Renal Cell) Cancer
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactSheila F Dropcho, RNPhone: 317-278-4191
Pager: 317-312-2512
Email: sdropcho@iupui.edu